LNP vs GalNAc Delivery for siRNA: Formulation and Manufacturing Considerations

Why Delivery Determines siRNA Development Success

Small interfering RNA (siRNA) therapeutics are designed to silence disease-related genes through RNA interference. The concept is elegant: a short double-stranded RNA molecule is introduced into cells, the guide strand is loaded into the RNA-induced silencing complex, and the complex directs sequence-specific degradation of the target mRNA. In practice, however, the success of siRNA is rarely determined by sequence design alone.

Delivery is often the decisive technical barrier.

Naked siRNA molecules are large, highly polar, negatively charged and vulnerable to nuclease degradation. They do not readily cross cell membranes and are rapidly cleared from circulation without chemical modification or a suitable delivery strategy. A sequence may show strong in vitro potency, but if it cannot reach the relevant tissue and enter the right cells at sufficient exposure, the program will not translate.

Modern siRNA development therefore depends on three connected decisions: the sequence and chemical modification pattern, the delivery platform, and the manufacturability of the final construct or formulation. Two delivery approaches have become especially important: lipid nanoparticle (LNP) formulation and N-acetylgalactosamine (GalNAc) conjugation. LNPs use a multicomponent lipid particle to protect and deliver RNA. GalNAc conjugates use a covalent ligand-based strategy to target hepatocytes through the asialoglycoprotein receptor (ASGPR).

Both platforms have clear strengths. LNPs are versatile formulation systems that can encapsulate nucleic acids and provide a path for broader delivery engineering. GalNAc conjugates are chemically defined constructs that have become especially valuable for liver-targeted siRNA programs. Choosing between them requires more than asking which platform is "better." The practical question is which platform matches the target tissue, dosing route, development stage, quality expectations, intellectual-property position and manufacturing strategy.

How LNP-Mediated siRNA Delivery Works

Lipid nanoparticles are nanoscale delivery systems usually built from four functional lipid components: an ionizable lipid, a helper phospholipid, cholesterol or another sterol component, and a PEG-lipid. Each component has a role in particle formation, stability, circulation behavior and intracellular delivery.

The ionizable lipid is often the most important component for activity. It is designed to remain relatively neutral at physiological pH, which helps reduce nonspecific toxicity in circulation. In the acidic endosomal environment, the ionizable lipid becomes protonated. This charge change promotes interaction with endosomal membranes and supports release of the RNA payload into the cytoplasm. Helper phospholipids contribute to membrane structure and fusion behavior. Cholesterol improves particle packing and stability. PEG-lipids help control particle size and reduce aggregation during formulation, although too much PEG shielding may reduce cellular uptake.

For siRNA, LNPs protect the RNA from degradation and improve cellular uptake, especially after systemic administration. The first approved siRNA drug using an LNP delivery system helped validate the approach clinically and accelerated interest in lipid-based nucleic acid delivery. The same delivery principles later supported broader development of LNP systems for mRNA vaccines and other RNA modalities.

From a process-development perspective, LNP delivery is powerful but complex. The final material is not a single molecule. It is a multicomponent nanoparticle system whose behavior depends on lipid structures, molar ratios, mixing conditions, particle size, polydispersity, encapsulation efficiency, pH, buffer composition, storage conditions and process history. Even subtle differences in lipid purity or formulation parameters can affect particle behavior.

How GalNAc Conjugation Enables Liver Targeting

GalNAc conjugation follows a different delivery logic. Instead of packaging siRNA inside a nanoparticle, the siRNA is covalently linked to a ligand recognized by receptors on hepatocytes. The central receptor is ASGPR, which is highly expressed on liver hepatocytes. Multivalent GalNAc ligands bind this receptor efficiently, triggering receptor-mediated endocytosis and internalization of the conjugated siRNA.

This makes GalNAc especially useful for liver-targeted gene silencing. GalNAc-siRNA conjugates are commonly designed for subcutaneous administration, which can be simpler for chronic treatment than intravenous infusion. Because the conjugate is a chemically defined entity, the control strategy can be more molecule-like than formulation-like. Developers can characterize intact mass, purity, conjugation completeness, impurity profile, water content, counterion content and related molecular attributes.

The success of GalNAc conjugation depends heavily on chemical modification of the siRNA itself. Since the conjugate does not rely on a particle to protect the RNA, stabilizing modifications such as 2'-O-methyl, 2'-fluoro and phosphorothioate linkages are commonly used to improve nuclease resistance, reduce immune stimulation and support longer duration of effect.

The main limitation is tissue scope. GalNAc delivery is strongest when the biology is liver-mediated. For targets outside the liver, GalNAc is generally not the first choice unless modulation of a liver-expressed gene can achieve the therapeutic objective. LNPs, by contrast, offer more room for biodistribution engineering, although extrahepatic delivery remains technically demanding.

LNP vs GalNAc: Key Technical Differences

LNP and GalNAc systems differ in several practical ways.

LNPs are supramolecular formulations. Their performance depends on both chemical composition and physical particle properties. GalNAc-siRNA conjugates are covalent molecular constructs in which the ligand, linker and oligonucleotide form a defined chemical entity.

LNPs have historically shown strong liver delivery after systemic administration, but they can be modified to explore other biodistribution profiles. GalNAc is primarily a hepatocyte-targeting strategy because it depends on ASGPR expression. LNP systems are often associated with intravenous administration in siRNA programs, while GalNAc conjugates are commonly designed for subcutaneous dosing.

Manufacturing also differs. LNP production requires controlled mixing of lipid and aqueous streams, followed by buffer exchange, concentration and particle-quality control. GalNAc conjugates require robust oligonucleotide synthesis, ligand/linker coupling, purification and molecular characterization. The LNP problem is often a formulation-engineering problem. The GalNAc problem is often a synthesis, conjugation and purification problem.

Analytical control follows the same split. LNPs require chemical and physical characterization: lipid identity, lipid impurities, RNA content, particle size, PDI, encapsulation efficiency, residual solvents, pH, osmolality, endotoxin and stability. GalNAc conjugates require molecular characterization: intact mass, sequence confirmation, conjugation purity, truncated impurities, extended impurities, depurination or deamination products, phosphorothioate-related complexity, residual solvents, water and counterions.

The comparison below is a useful early-stage screening tool. It is not a substitute for program-specific evaluation, but it helps teams ask the right questions before committing to a delivery route.

The practical takeaway is that LNP and GalNAc programs put pressure on different parts of the supply chain. LNP programs require consistent lipid chemistry and formulation-aware documentation. GalNAc programs require precise building blocks, linkers and oligonucleotide-compatible conjugation chemistry. For CHEMOS, this difference matters because the most relevant service position is not "one delivery platform is better." It is helping customers secure the materials that make either platform developable.

Manufacturing Considerations for LNP Formulations

LNP manufacturing is sensitive to formulation and process parameters. A common approach dissolves lipids in an organic solvent such as ethanol and rapidly mixes this lipid phase with an aqueous phase containing nucleic acid. As the solvent environment changes, the lipids self-assemble into nanoparticles and associate with the RNA payload.

Lipid quality is a first-order concern. Ionizable lipids, PEG-lipids, helper phospholipids and sterols must meet appropriate purity and documentation expectations. Oxidation, hydrolysis, residual synthetic impurities, isomeric composition and storage sensitivity can all affect formulation performance. Unsaturated lipids require special attention because oxidation products may alter particle behavior or stability.

Mixing control is equally important. Particle formation occurs quickly. If mixing is uneven, particle size distribution can broaden, encapsulation efficiency may drop, and batch-to-batch consistency can suffer. During scale-up, simply increasing channel size or batch volume may change mixing behavior. Many development teams therefore prefer numbering-up strategies, where multiple controlled mixing units are operated in parallel rather than relying on one enlarged mixing path.

Post-formulation processing adds another layer. Ethanol and buffer components often need to be removed or exchanged through tangential flow filtration or dialysis-like processes. The formulation may require sterile filtration, fill-finish, refrigerated or frozen storage, and sometimes lyophilization. Each step can influence particle size, aggregation, RNA retention and stability.

For material suppliers and custom synthesis partners, this means LNP support is not just a catalog-lipid business. It also involves impurity understanding, oxidation-sensitive handling, analytical documentation, packaging, storage recommendations and reliable batch consistency.

For customers sourcing LNP-related lipids, the procurement question should go beyond price and nominal purity. A formulation team may need to know whether the lipid was isolated as a neutral form or salt, whether residual acid or base remains from the final step, whether unsaturated chains were protected from oxidation, whether a peroxide or oxidation marker has been checked, and whether the same route can support follow-up batches. These questions are especially important for novel ionizable lipids, where the structure-performance relationship is still being established.

When a lipid is used only for early screening, flexible documentation may be acceptable. Once the same lipid becomes a lead formulation component, the quality package should become more disciplined. At that stage, batch records, chromatographic method consistency, impurity tracking and storage data help reduce the risk that formulation changes are mistaken for biological effects.

Chemistry and Linker Considerations for GalNAc Conjugates

GalNAc-siRNA conjugates combine three design elements: the siRNA sequence, the chemical modification pattern and the GalNAc ligand-linker architecture.

The GalNAc ligand is often presented in a multivalent format to improve ASGPR binding. Triantennary GalNAc designs are widely used because multivalent receptor engagement improves hepatocyte uptake. The ligand is connected to the oligonucleotide through a linker or spacer that may influence synthetic accessibility, stability, receptor recognition and overall molecular properties.

The linker must be stable enough to survive synthesis, purification, storage and administration. At the same time, it should not interfere with receptor binding or RNAi activity. Linker length, hydrophilicity, steric bulk, branching architecture and conjugation site can all matter. These choices may look minor on paper, but they can strongly affect process development.

From a manufacturing standpoint, GalNAc conjugates create challenges in solid-phase synthesis and purification. Modified nucleoside phosphoramidites, phosphorothioate linkages and GalNAc-containing building blocks may show different coupling efficiencies. Large or branched ligand structures may require longer coupling times, higher reagent excess or process optimization. Incomplete coupling can produce closely related impurities that are difficult to separate.

A practical GalNAc building block specification should consider more than identity and purity. If the material contains protected hydroxyl groups, the protecting-group pattern must be clear. If the material carries an activated ester, azide, alkyne, amine or acid handle, functional group integrity should be confirmed. If a branching scaffold is used, positional isomers and partially substituted species may become important impurities. For conjugation teams, these details can determine whether a building block behaves predictably in a downstream synthesis.

Quality Attributes for siRNA Delivery Systems

For LNPs, important quality attributes include particle size, PDI, encapsulation efficiency, RNA concentration, lipid composition, lipid impurity profile, residual solvent, pH, osmolality, endotoxin and stability under storage conditions. Research-stage materials may focus on identity, purity, COA, storage and handling. Later-stage programs require more extensive method validation and stability data.

For GalNAc-siRNA conjugates, quality attributes include molecular identity, intact mass, sequence confirmation, purity, truncated impurities, extended impurities, depurination or deamination products, phosphorothioate-related complexity, ligand conjugation completeness, water content, residual solvents, counterion profile and stability. Analytical methods may include HPLC, LC-MS, UV, capillary electrophoresis, Karl Fischer titration, ion chromatography and NMR.

The practical distinction is simple: LNPs require physical particle characterization in addition to chemical analysis, while GalNAc conjugates require deep molecular characterization of a covalent construct.

How CHEMOS Supports LNP and GalNAc-Related Materials

CHEMOS supports advanced chemistry projects involving LNP-related lipids, GalNAc-related building blocks, functional linkers, PEG spacers, custom synthesis, route development, process optimization and analytical support. For nucleic acid delivery programs, reliable access to high-quality materials is essential because small differences in structure, purity, impurity profile or storage condition can affect downstream formulation or conjugation work.

For LNP projects, CHEMOS can support the preparation or custom synthesis of ionizable lipids, helper lipids, PEG-lipid-related materials, sterol derivatives and related intermediates according to project-specific structures and specifications. Technical discussions may include route feasibility, impurity control, oxidation-sensitive handling, batch size, documentation and packaging.

For GalNAc-related projects, CHEMOS can support GalNAc building blocks, linker intermediates, activated functional handles and specialty materials used in conjugation chemistry. These materials often require careful control of stereochemistry, protecting groups, residual impurities and functional group integrity.

FAQ

What is the main difference between LNP and GalNAc delivery for siRNA?

LNP delivery uses a lipid nanoparticle formulation to protect and transport siRNA. GalNAc delivery uses a covalent ligand-siRNA conjugate that targets hepatocytes through ASGPR.

Which platform is better for liver-targeted siRNA?

GalNAc conjugation is highly effective for liver-targeted siRNA programs. LNPs can also deliver siRNA to the liver, but they involve a more complex nanoparticle formulation.

Why are ionizable lipids important in LNPs?

Ionizable lipids support nucleic acid association during formulation and endosomal escape after cellular uptake. Their pH-dependent charge behavior is central to LNP delivery.

Can CHEMOS support custom materials for LNP or GalNAc projects?

Yes. CHEMOS can support custom synthesis and process development for LNP-related lipids, GalNAc-related building blocks, linkers, PEG spacers and functional handles.

References and Further Reading

1. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery, 2020. https://doi.org/10.1038/s41573-020-0075-7
2. Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nature Reviews Drug Discovery, 2019. https://doi.org/10.1038/s41573-019-0017-4
3. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2021. https://doi.org/10.1038/s41578-021-00358-0
4. Cullis PR, Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. Molecular Therapy, 2017. https://doi.org/10.1016/j.ymthe.2017.03.013
5. Nair JK, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. Journal of the American Chemical Society, 2014. https://doi.org/10.1021/ja505986a
6. Akinc A, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology, 2019. https://doi.org/10.1038/s41565-019-0591-y
7. FDA. Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry, 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry